戻る Agenda
Session 7: Case Study: COVID R&D Alliance, RWE Informing COVID-19 Drug Development and Closing Remarks
Session Chair(s)
Brian Bradbury, DrSc, MA
Vice President, Center for Observational Research
Amgen, United States
Marni Hall, PhD, MPH
VP & GM, Global Regulatory Science and Strategy
IQVIA, United States
This session provides an introduction to the COVID R&D Alliance and how the use of RWE is assisting in the design of platforms trials and providing evidence regarding the natural history of disease for patients diagnosed with COVID-19. Emphasis will be placed on the value of coordinated and collaborative engagement across manufactures and the lessons learned from this effort.
Learning Objective : - Describe the COVID R&D Alliance and the collaborative approach that manufacturers are taking to accelerate the testing of repurposed medicines as potential treatment
- Discuss ongoing R&D Alliance RWE studies designed to better inform on the natural history of disease and the safety of treatments
- Apply lessons learned from COVID R&D Alliance RWE collaborations to research efforts in the post-COVID environment
Speaker(s)
Speaker
Anne Heatherington, PhD
Takeda Pharmaceuticals, United States
Senior Vice President, Head of Data Sciences Institute
Speaker
Cathy W Critchlow, PhD, MSc
Amgen, Inc, United States
Vice President, R&D Data Strategy
Speaker
Ying Bao, DrSc, MD
Bristol Myers Squibb, United States
Senior Director, Center for Observational Research and Data Science
Closing Remarks
Brian Bradbury, DrSc, MA
Amgen, United States
Vice President, Center for Observational Research